# Spur Capital Partners

> Spur Capital Partners is a VC fund backing Health Care and Medical. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Bartlesville, United States
- Total investments: 5
- Last investment: Feb 2026
- Lead investor: 40%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company-beta/1206636/?pathWildcard=1206636
- X (Twitter): https://twitter.com/SpurVentures
- Website: http://www.spurcapital.com/

Spur Capital Partners is a VC fund in Bartlesville focused on Health Care and Medical. Spur Capital focuses primarily on early-stage, technology-centric, U.S. venture capital partnerships. We have a successful history of durable relationships with top-tier venture capital firms as well as uncovering up-and-coming firms. Our limited partners are leading private foundations, endowments and institutional investors in the United Statesand Western Europe.

## Contacts

5 contacts available for Spur Capital Partners. Shizune tracks 7 team members at Spur Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/spur-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 40% |
| Medical | 1 | 20% |
| Biopharma | 1 | 20% |
| Therapeutics | 1 | 20% |
| Biotechnology | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series E | 1 | 20% |
| Series F | 1 | 20% |
| Funding Round | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| C. Bradford Kelly | Managing Director and Co-Founder | 0 | https://shizune.co/investors/profile/c-bradford-kelly |
| Joan Heidorn | Managing Director and Co-Founder | 0 | https://shizune.co/investors/profile/joan-heidorn |
| John Czerwionka | Partner | 0 | https://shizune.co/investors/profile/john-czerwionka-46f1 |
| Matt Horten | Managing Director | 0 | https://shizune.co/investors/profile/matt-horten |
| Paul Fetsch | Managing Director and Co-Founder | 0 | https://shizune.co/investors/profile/paul-fetsch |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Axis Medical | Axis Medical Group is a Denver-based distributor of orthopedic surgical supplies, with a strong focus on spinal biologics, implants, and related products.The company specializes in distributing innovative orthopedic products from over 20 OEM manufacturers, emphasizing boutique ortho biologics, disk replacement, fixation, spine fusion, and generalspine solutions. They manage logistics, inventory management, and surgeon education to support operating rooms efficiently. Their services extend across the Western US, prioritizing regulatory compliance and surgeon relationships. |  | Venture - Series Unknown | Feb 19, 2026 |  |
| Axis Medical | Axis Medical Group is a Denver-based distributor of orthopedic surgical supplies, with a strong focus on spinal biologics, implants, and related products.The company specializes in distributing innovative orthopedic products from over 20 OEM manufacturers, emphasizing boutique ortho biologics, disk replacement, fixation, spine fusion, and generalspine solutions. They manage logistics, inventory management, and surgeon education to support operating rooms efficiently. Their services extend across the Western US, prioritizing regulatory compliance and surgeon relationships. |  | Venture - Series Unknown | Feb 19, 2026 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M |  | Apr 03, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M | Series F | Apr 03, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $120M | Series E | Feb 08, 2024 |  |

5 of 5 investments shown.

## Co-investors
- [Schroders Capital](https://shizune.co/investors/profile/schroders-capital) — VC Fund, 3 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 3 deals together
- [UCB Ventures](https://shizune.co/investors/profile/ucb-ventures) — VC Fund, 3 deals together
- [UC Investments](https://shizune.co/investors/profile/uc-investments) — VC Fund, 3 deals together
- [Viking Global Investors](https://shizune.co/investors/profile/viking-global-investors) — VC Fund, 3 deals together
- [Willett Advisors LLC](https://shizune.co/investors/profile/willett-advisors-llc) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Krungsri Finnovate](https://shizune.co/investors/profile/krungsri-finnovate) — VC Fund
- [Munich Venture Partners](https://shizune.co/investors/profile/munich-venture-partners) — VC Fund
- [yet2Ventures](https://shizune.co/investors/profile/yet2ventures) — VC Fund

## FAQ

### What does Spur Capital Partners invest in?

Spur Capital Partners invests primarily in Health Care, Medical and Biopharma startups, most often at Series E and Series F stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Spur Capital Partners?

Public channels for Spur Capital Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Spur Capital Partners?

The team at Spur Capital Partners includes C. Bradford Kelly (Managing Director and Co-Founder), Joan Heidorn (Managing Director and Co-Founder) and John Czerwionka (Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co